Waltham, MA, United States of America

Hedy Adari

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Visterra, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hedy Adari. Retrieved from https://idiyas.com/inventor/hedy-adari

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hedy Adari and Patent Innovation in Complement-Mediated Disease Treatment.

Introduction

Hedy Adari is an inventor associated with Waltham, Massachusetts, and Visterra, Inc. Her patent work concerns antibody-based approaches to treating diseases and disorders involving the complement system.

Latest Patents

Adari is listed as an inventor on 1 patent: “Treatment of Complement Mediated Diseases and Disorders with C3b Antibodies.” The patent describes the use of C3b antibodies in addressing complement-mediated conditions.

Career Highlights

Adari’s listed patent reflects work at the intersection of antibody research and therapeutic development. Her association with Visterra, Inc. connects her invention to a company focused on developing antibody-based medicines.

Collaborations

Adari’s listed coworkers include Karthik Viswanathan and Ramki Ramakrishnan. Their shared association with the patent record highlights collaborative contributions to research on C3b antibodies and complement-mediated diseases.

Conclusion

Hedy Adari’s patent activity centers on a C3b antibody approach to complement-mediated diseases and disorders, reflecting her contribution to therapeutic innovation at Visterra, Inc.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…